Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2021 08:00 ET | Source: Pyxis Oncology

Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the "Company") today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional...
April 19, 2021 09:03 ET | Source: Pyxis Oncology

Pyxis Oncology Hosting Key Opinion Webinar on Antibody-Drug Conjugates

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology ("Pyxis" or the "Company") today announced that it will host a key opinion leader (KOL) webinar on antibody-drug conjugates on...
March 30, 2021 08:00 ET | Source: Pyxis Oncology

Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics

-- New round enables Pyxis to advance differentiated antibody-drug conjugate (ADC) and immuno-oncology (I/O) programs to next value inflection point -- -- In addition to recently announced...
March 18, 2021 08:00 ET | Source: Pyxis Oncology

Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology (“Pyxis” or the "Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for...